The Febrile Neutropenia drugs in development market research report provides comprehensive information on the therapeutics under development for Febrile Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Febrile Neutropenia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Febrile Neutropenia by 12 companies/universities/institutes. The top development phase for Febrile Neutropenia is preclinical with three drugs in that stage. The Febrile Neutropenia pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Febrile Neutropenia pipeline products market are: Biogenomics, Kexing Biopharm and Akthelia Pharmaceuticals.
The key targets in the Febrile Neutropenia pipeline products market include Granulocyte Colony Stimulating Factor Receptor, Caspase 9, and Caspase 8.
The key mechanisms of action in the Febrile Neutropenia pipeline product include Granulocyte Colony Stimulating Factor Receptor Agonist with ten drugs in Pre-Registration. The Febrile Neutropenia pipeline products include four routes of administration with the top ROA being Subcutaneous and three key molecule types in the Febrile Neutropenia pipeline products market including Recombinant Protein, and Small Molecule.
Febrile Neutropenia overview
Febrile neutropenia or neutropenic fever is a defined as a single oral temperature value of ≥ 38.3 C (101 F) or a temperature ≥ 38 C (100.4 F) for ≥ 1 hour, with an absolute neutrophil count (ANC) < 1500 cell/microliter. It is the development of fever, often with other signs of infection, in a patient with neutropenia, an abnormally low number of neutrophil granulocytes (a type of white blood cell) in the blood. It is an oncologic emergency, and is the most common serious complication in patients with hematopoietic cancers or receiving chemotherapy for cancer. Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells).
For a complete picture of Febrile Neutropenia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
